In glioblastoma, SRPX2 knockdown significantly decreased the expression of EMT markers (N-cadherin, fibronectin, Twist, Snail, and Slug) and increased E-cadherin expression, while SRPX2 overexpression increased N-cadherin and fibronectin expression and decreased E-cadherin expression. The gene discussed is FN1; the disease is glioblastoma.